To evaluate the therapeutic potential of ML364 in a syngeneic mouse model, p53-wild-type EMT6 tumor cells were injected subcutaneously into the right flank of immunocompetent Balb/c mice and tumor growth was monitored every 2–3 days. The gene discussed is TP53; the disease is neoplasm.